<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710811</url>
  </required_header>
  <id_info>
    <org_study_id>INSULIN001</org_study_id>
    <nct_id>NCT03710811</nct_id>
  </id_info>
  <brief_title>Observational Study of Drug Naive Diabetes Receiving Insulin Therapy</brief_title>
  <official_title>Observational Study of Drug Naive Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre, open-label trial to investigate the efficacy and possible mechanism of&#xD;
      Continuous Subcutaneous Insulin Infusion treatment in patients with drug naive type 2&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating immunity cell profiles</measure>
    <time_frame>7 days</time_frame>
    <description>profiles of circulating immunity cells such as T cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>skeletal muscle parameter</measure>
    <time_frame>7 days</time_frame>
    <description>skeletal muscle parameters in magnetic resonance imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>fasting blood glucose</measure>
    <time_frame>7 days</time_frame>
    <description>fasting blood glucose</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <description>drug naive Type 2 Diabetes received insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal control</arm_group_label>
    <description>healthy volunteers as normal control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Continuous Subcutaneous Insulin Infusion</description>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample with DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        drug naive type 2 diabetes and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        for type 2 diabetes:&#xD;
&#xD;
          1. Male or female age ≧ 25 years and ≦75 years old&#xD;
&#xD;
          2. HbA1c ≧8.0%&#xD;
&#xD;
          3. durg naive&#xD;
&#xD;
        for normal controls：&#xD;
&#xD;
          1. Male or female age ≧ 25 years and ≦75 years old&#xD;
&#xD;
          2. Normal glucose tolerance confirmed by oral glucose tolerance test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Islet antibody positive&#xD;
&#xD;
          2. Athletes, has a history of skeletal muscle injury ( trauma or surgery ), skeletal&#xD;
             muscle wasting diseases ( such as mitochondrial myopathy, muscular atrophy, etc )&#xD;
&#xD;
          3. Acute infection(such as cute upper respiratory infection, acute pneumonia)&#xD;
&#xD;
          4. long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and&#xD;
             immunosuppressive drugs&#xD;
&#xD;
          5. consists with other endocrine diseases&#xD;
&#xD;
          6. pregnancy&#xD;
&#xD;
          7. cancer&#xD;
&#xD;
          8. use of antibiotics in 3 months&#xD;
&#xD;
          9. chronic digestive inflammations&#xD;
&#xD;
         10. magnetic resonance imaging contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalong Zhu, MD,PhD</last_name>
      <phone>86-25-83-105302</phone>
      <email>zhudldr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Bi, MD,PhD</last_name>
      <phone>86-25-83-105302</phone>
      <email>biyan@nju.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Dalong Zhu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Bi, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People'S Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiao ye, MD</last_name>
      <phone>86-571-85893937</phone>
    </contact>
    <investigator>
      <last_name>xiao ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Dalong Zhu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>insulin</keyword>
  <keyword>drug naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

